Show simple item record

dc.contributor.authorPais, H
dc.contributor.authorRuggero, K
dc.contributor.authorZhang, J
dc.contributor.authorAl-Assar, O
dc.contributor.authorBery, N
dc.contributor.authorBhuller, R
dc.contributor.authorWeston, V
dc.contributor.authorKearns, PR
dc.contributor.authorMecucci, C
dc.contributor.authorMiller, A
dc.contributor.authorRabbitts, TH
dc.date.accessioned2019-10-21T08:58:02Z
dc.date.issued2019-04-08
dc.identifier.citationScientific reports, 2019, 9 (1), pp. 5760 - ?
dc.identifier.issn2045-2322
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3383
dc.identifier.eissn2045-2322
dc.identifier.doi10.1038/s41598-019-42214-w
dc.description.abstractThe surfaceome is critical because surface proteins provide a gateway for internal signals and transfer of molecules into cells, and surfaceome differences can influence therapy response. We have used a surfaceome analysis method, based on comparing RNA-seq data between normal and abnormal cells (Surfaceome DataBase Mining or Surfaceome DBM), to identify sets of upregulated cell surface protein mRNAs in an LMO2-mediated T-ALL mouse model and corroborated by protein detection using antibodies. In this model the leukemia initiating cells (LICs) comprise pre-leukaemic, differentiation inhibited thymocytes allowing us to provide a profile of the LIC surfaceome in which GPR56, CD53 and CD59a are co-expressed with CD25. Implementation of cell surface interaction assays demonstrates fluid interaction of surface proteins and CD25 is only internalized when co-localized with other proteins. The Surfaceome DBM approach to analyse cancer cell surfaceomes is a way to find targetable surface biomarkers for clinical conditions where RNA-seq data from normal and abnormal cell are available.
dc.formatElectronic
dc.format.extent5760 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCells, Cultured
dc.subjectCell Membrane
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectAdaptor Proteins, Signal Transducing
dc.subjectReceptors, G-Protein-Coupled
dc.subjectProto-Oncogene Proteins
dc.subjectInterleukin-2 Receptor alpha Subunit
dc.subjectLeukemia, Lymphoid
dc.subjectNeoplastic Stem Cells
dc.subjectHEK293 Cells
dc.subjectLIM Domain Proteins
dc.subjectTranscriptome
dc.subjectBiomarkers, Tumor
dc.subjectCD59 Antigens
dc.subjectTetraspanin 25
dc.subjectRNA-Seq
dc.titleSurfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model.
dc.typeJournal Article
dcterms.dateAccepted2019-03-27
rioxxterms.versionofrecord10.1038/s41598-019-42214-w
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-04-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfScientific reports
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
icr.researchteamChromosomal Translocations and Intracellular Antibody Therapeuticsen_US
dc.contributor.icrauthorRabbitts, Terenceen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0